Krystal Biotech, Inc. Operating Income
Krystal Biotech, Inc. (KRYS) reported Operating Income of $58.42 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-03
- Krystal Biotech, Inc. operating income (loss) for the quarter ending 2026-06-30 was $58.42M, a 48.27% increase year-over-year.
- Krystal Biotech, Inc. operating income (loss) for the quarter ending 2026-03-31 was $53.69M, a 48.10% increase year-over-year.
- Krystal Biotech, Inc. operating income (loss) for the quarter ending 2025-12-31 was $44.27M, a 7.00% increase year-over-year.
- Krystal Biotech, Inc. operating income (loss) for the quarter ending 2025-09-30 was $41.37M, a 84.11% increase year-over-year.
- Krystal Biotech, Inc. operating income (loss) for fiscal 2025 was $161.29M, a 145.32% increase from fiscal 2024.
- Krystal Biotech, Inc. operating income (loss) for fiscal 2024 was $65.75M.
- Krystal Biotech, Inc. operating income (loss) for fiscal 2023 was -$109.62M.
- Krystal Biotech, Inc. operating income (loss) for fiscal 2022 was -$145.20M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 3 month as first filed | Operating Income (Loss) 6 month | Operating Income (Loss) 6 month as first filed | Operating Income (Loss) 9 month | Operating Income (Loss) 9 month as first filed | Operating Income (Loss) 12 month | Operating Income (Loss) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $58.42M 10-Q · filed 2026-08-03 | $112.11M 10-Q · filed 2026-08-03 | $156.38M derived: sum of 3 quarters · filed 2026-08-03 | $197.75M derived: sum of 4 quarters · filed 2026-08-03 | ||||
| 2026-03-31 | $53.69M 10-Q · filed 2026-05-04 | $97.96M derived: sum of 2 quarters · filed 2026-05-04 | $139.33M derived: sum of 3 quarters · filed 2026-05-04 | $178.73M derived: sum of 4 quarters · filed 2026-08-03 | ||||
| 2025-12-31 | $44.27M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $85.64M derived: sum of 2 quarters · filed 2026-02-17 | $125.04M derived: sum of 3 quarters · filed 2026-08-03 | $161.29M 10-K · filed 2026-02-17 | ||||
| 2025-09-30 | $41.37M 10-Q · filed 2025-11-03 | $80.77M derived: sum of 2 quarters · filed 2026-08-03 | $117.03M 10-Q · filed 2025-11-03 | $158.40M derived: sum of 4 quarters · filed 2026-08-03 | ||||
| 2025-06-30 | $39.40M 10-Q · filed 2026-08-03 | $39.31M 10-Q · filed 2025-08-04 | $75.65M 10-Q · filed 2026-08-03 | $75.48M 10-Q · filed 2025-08-04 | $117.03M derived: sum of 3 quarters · filed 2026-08-03 | $139.50M derived: sum of 4 quarters · filed 2026-08-03 | ||
| 2025-03-31 | $36.25M 10-Q · filed 2026-05-04 | $36.18M 10-Q · filed 2025-05-06 | $77.63M derived: sum of 2 quarters · filed 2026-05-04 | $100.10M derived: sum of 3 quarters · filed 2026-05-04 | $108.67M derived: sum of 4 quarters · filed 2026-05-04 | |||
| 2024-12-31 | $41.38M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $63.85M derived: sum of 2 quarters · filed 2026-02-17 | $72.41M derived: sum of 3 quarters · filed 2026-02-17 | $65.75M 10-K · filed 2026-02-17 | $65.69M 10-K · filed 2025-02-19 | |||
| 2024-09-30 | $22.47M 10-Q · filed 2025-11-03 | $22.43M 10-Q · filed 2024-11-04 | $31.04M derived: sum of 2 quarters · filed 2025-11-03 | $24.37M 10-Q · filed 2025-11-03 | $24.32M 10-Q · filed 2024-11-04 | $27.60M derived: sum of 4 quarters · filed 2026-02-17 | ||
| 2024-06-30 | $8.57M 10-Q · filed 2025-08-04 | $1.88M 10-Q · filed 2025-08-04 | $5.13M derived: sum of 3 quarters · filed 2026-02-17 | -$20.86M derived: sum of 4 quarters · filed 2026-02-17 | ||||
| 2024-03-31 | -$6.68M 10-Q · filed 2025-05-06 | -$3.44M derived: sum of 2 quarters · filed 2026-02-17 | -$29.43M derived: sum of 3 quarters · filed 2026-02-17 | -$67.48M derived: sum of 4 quarters · filed 2026-02-17 | ||||
| 2023-12-31 | $3.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | -$22.75M derived: sum of 2 quarters · filed 2026-02-17 | -$60.79M derived: sum of 3 quarters · filed 2026-02-17 | -$109.62M 10-K · filed 2026-02-17 | -$109.73M 10-K · filed 2024-02-26 | |||
| 2023-09-30 | -$25.99M 10-Q · filed 2024-11-04 | -$64.04M derived: sum of 2 quarters · filed 2024-11-04 | -$112.86M 10-Q · filed 2024-11-04 | -$147.63M derived: sum of 4 quarters · filed 2025-02-19 | ||||
| 2023-06-30 | -$38.05M 10-Q · filed 2024-08-05 | -$86.87M 10-Q · filed 2024-08-05 | -$121.64M derived: sum of 3 quarters · filed 2025-02-19 | -$153.09M derived: sum of 4 quarters · filed 2025-02-19 | ||||
| 2023-03-31 | -$48.82M 10-Q · filed 2024-05-06 | -$83.59M derived: sum of 2 quarters · filed 2025-02-19 | -$115.05M derived: sum of 3 quarters · filed 2025-02-19 | -$143.80M derived: sum of 4 quarters · filed 2025-02-19 | ||||
| 2022-12-31 | -$34.77M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | -$66.22M derived: sum of 2 quarters · filed 2025-02-19 | -$94.97M derived: sum of 3 quarters · filed 2025-02-19 | -$145.20M 10-K · filed 2025-02-19 | ||||
| 2022-09-30 | -$31.45M 10-Q · filed 2023-11-06 | -$60.20M derived: sum of 2 quarters · filed 2023-11-06 | -$110.42M 10-Q · filed 2023-11-06 | -$132.30M derived: sum of 4 quarters · filed 2024-02-26 | ||||
| 2022-06-30 | -$28.75M 10-Q · filed 2023-08-07 | -$78.97M 10-Q · filed 2023-08-07 | -$100.85M derived: sum of 3 quarters · filed 2024-02-26 | -$116.50M derived: sum of 4 quarters · filed 2024-02-26 | ||||
| 2022-03-31 | -$50.22M 10-Q · filed 2023-05-08 | -$72.10M derived: sum of 2 quarters · filed 2024-02-26 | -$87.75M derived: sum of 3 quarters · filed 2024-02-26 | -$104.14M derived: sum of 4 quarters · filed 2024-02-26 | ||||
| 2021-12-31 | -$21.88M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | -$37.53M derived: sum of 2 quarters · filed 2024-02-26 | -$53.92M derived: sum of 3 quarters · filed 2024-02-26 | -$68.28M 10-K · filed 2024-02-26 | ||||
| 2021-09-30 | -$15.65M 10-Q · filed 2022-11-07 | -$32.05M derived: sum of 2 quarters · filed 2022-11-07 | -$46.40M 10-Q · filed 2022-11-07 | -$56.82M derived: sum of 4 quarters · filed 2023-02-27 | ||||
| 2021-06-30 | -$16.39M 10-Q · filed 2022-08-08 | -$30.75M 10-Q · filed 2022-08-08 | -$41.17M derived: sum of 3 quarters · filed 2023-02-27 | -$50.85M derived: sum of 4 quarters · filed 2023-02-27 | ||||
| 2021-03-31 | -$14.35M 10-Q · filed 2022-05-09 | -$24.77M derived: sum of 2 quarters · filed 2023-02-27 | -$34.45M derived: sum of 3 quarters · filed 2023-02-27 | -$41.41M derived: sum of 4 quarters · filed 2023-02-27 | ||||
| 2020-12-31 | -$10.42M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | -$20.10M derived: sum of 2 quarters · filed 2023-02-27 | -$27.05M derived: sum of 3 quarters · filed 2023-02-27 | -$33.00M 10-K · filed 2023-02-27 | ||||
| 2020-09-30 | -$9.68M 10-Q · filed 2021-11-08 | -$16.63M derived: sum of 2 quarters · filed 2021-11-08 | -$22.58M 10-Q · filed 2021-11-08 | -$28.73M derived: sum of 4 quarters · filed 2021-11-08 | ||||
| 2020-06-30 | -$6.95M 10-Q · filed 2021-08-09 | -$12.90M 10-Q · filed 2021-08-09 | -$19.05M derived: sum of 3 quarters · filed 2021-08-09 | -$24.40M derived: sum of 4 quarters · filed 2021-08-09 | ||||
| 2020-03-31 | -$5.95M 10-Q · filed 2021-05-10 | -$12.10M derived: sum of 2 quarters · filed 2021-05-10 | -$17.44M derived: sum of 3 quarters · filed 2021-05-10 | -$23.33M derived: sum of 4 quarters · filed 2021-05-10 | ||||
| 2019-12-31 | -$6.15M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | -$11.50M derived: sum of 2 quarters · filed 2021-03-01 | -$17.39M derived: sum of 3 quarters · filed 2021-03-01 | -$22.08M 10-K · filed 2021-03-01 | ||||
| 2019-09-30 | -$5.34M 10-Q · filed 2020-11-09 | -$11.23M derived: sum of 2 quarters · filed 2020-11-09 | -$15.93M 10-Q · filed 2020-11-09 | -$20.14M derived: sum of 4 quarters · filed 2020-11-09 | ||||
| 2019-06-30 | -$5.89M 10-Q · filed 2020-08-07 | -$10.59M 10-Q · filed 2020-08-07 | -$14.80M derived: sum of 3 quarters · filed 2020-08-07 | -$17.77M derived: sum of 4 quarters · filed 2020-08-07 | ||||
| 2019-03-31 | -$4.69M 10-Q · filed 2020-05-04 | -$8.91M derived: sum of 2 quarters · filed 2020-05-04 | -$11.88M derived: sum of 3 quarters · filed 2020-05-04 | -$14.33M derived: sum of 4 quarters · filed 2020-05-04 | ||||
| 2018-12-31 | -$4.22M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-10 | -$7.19M derived: sum of 2 quarters · filed 2020-03-10 | -$9.64M derived: sum of 3 quarters · filed 2020-03-10 | -$11.92M 10-K · filed 2020-03-10 | ||||
| 2018-09-30 | -$2.97M 10-Q · filed 2019-11-04 | -$5.42M derived: sum of 2 quarters · filed 2019-11-04 | -$7.70M 10-Q · filed 2019-11-04 | -$9.20M derived: sum of 4 quarters · filed 2019-11-04 | ||||
| 2018-06-30 | -$2.45M 10-Q · filed 2019-08-05 | -$4.73M 10-Q · filed 2019-08-05 | -$6.22M derived: sum of 3 quarters · filed 2019-08-05 | -$8.32M derived: sum of 4 quarters · filed 2019-08-05 | ||||
| 2018-03-31 | -$2.28M 10-Q · filed 2019-05-07 | -$3.77M derived: sum of 2 quarters · filed 2019-05-07 | -$5.87M derived: sum of 3 quarters · filed 2019-05-07 | -$6.58M derived: sum of 4 quarters · filed 2019-05-07 | ||||
| 2017-12-31 | -$1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | -$3.59M derived: sum of 2 quarters · filed 2018-11-05 | -$4.31M derived: sum of 3 quarters · filed 2018-11-05 | -$4.77M 10-K · filed 2018-03-12 | ||||
| 2017-09-30 | -$2.09M 10-Q · filed 2018-11-05 | -$2.81M derived: sum of 2 quarters · filed 2018-11-05 | -$3.27M 10-Q · filed 2018-11-05 | -$3.89M derived: sum of 4 quarters · filed 2018-11-05 | ||||
| 2017-06-30 | -$715.00K 10-Q · filed 2018-08-06 | -$1.18M 10-Q · filed 2018-08-06 | -$1.80M derived: sum of 3 quarters · filed 2018-08-06 | -$2.12M derived: sum of 4 quarters · filed 2018-08-06 | ||||
| 2017-03-31 | -$465.00K 10-Q · filed 2018-05-07 | -$1.08M derived: sum of 2 quarters · filed 2018-05-07 | -$1.41M derived: sum of 3 quarters · filed 2018-05-07 | |||||
| 2016-12-31 | -$620.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | -$942.00K derived: sum of 2 quarters · filed 2018-03-12 | -$1.14M 10-K · filed 2018-03-12 | |||||
| 2016-09-30 | -$322.00K 10-Q · filed 2017-11-13 | -$523.00K 10-Q · filed 2017-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |